• 15 February 2012

    AiCuris reports efficacy data of Letermovir drug

    AiCuris' Letermovir (AIC246) has met its primary efficacy endpoints in a Phase 2 trial for the control of human cytomegalovirus (HCMV) prophylaxis in human blood precursor cell (HBPC) recipients.

  • 14 February 2012

    Celsion enrols first patient in ThermoDox phase II study

    Celsion Corporation has enrolled the first patient in its randomised Phase II study of ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, plus radiofrequency ablation (RFA), used as a treatment for...

  • 13 February 2012

    Santarus initiates patient enrolment in Uceris study

    Santarus has commenced patient enrolment in a multicentre, randomised, double-blind, placebo-controlled Phase IIIb trial of its UCERIS (budesonide) tablets 9mg, used to treat patients with mild or moderate ulcerative colitis.

  • 12 February 2012

    Altheos doses first patient in glaucoma drug trial

    Altheos has dosed the first patient in a Phase 2a clinical trial of its investigational drug candidate ATS907, a Rho kinase (ROCK)-selective inhibitor used as a next-generation eye drop for...

  • 12 February 2012

    Soligenix reports phase 1/2 trial data of SGX201

    Soligenix, a development stage biopharmaceutical company, has reported the preliminary results from its Phase 1/2 clinical study of SGX201, a time-release formulation of oral beclomethasone 17,21-dipropionate (oral BDP), used for...